Maria Pagano, Luca Giovanni Ceresoli, Paolo Andrea Zucali, Giulia Pasello, Marina Garassino, Federica Grosso, Marcello Tiseo, Hector Soto Parra, Francesca Zanelli, Federico Cappuzzo, Francesco Grossi, Filippo De Marinis, Paolo Pedrazzoli, Roberta Gnoni, Candida Bonelli, Federica Torricelli, Alessia Ciarrocchi, Nicola Normanno, Carmine Pinto
Purpose: Malignant pleural mesothelioma (MPM) is an aggressive cancer. Data are not available in prospective trials on correlations between genetic alterations and outcomes of therapies. In this study, we assessed the genetic profile of MPM patients (pts) in tissue samples. Patients and Methods: From December 2016 to July 2018 (end of enrolment), 164 pts were enrolled. We evaluated by targeted sequencing the mutational profile of a panel of 34 genes: ACTB , ACTG1 , ACTG2 , ACTR1A , BAP1 , CDH8 , CDK4 , CDKN2A , CDKN2B , COL3A1 , COL5A2 , CUL1 , DHFR , GOT1 , KDR , KIT , MXRA5 , NF2 , NFRKB , NKX6-2 , NOD2 , PCBD2 , PDZK1IP1 , PIK3CA , PIK3CB , PSMD13 , RAPGEF6 , RDX , SETDB1 , TAOK1 , TP53 , TXNRD1 , UQCRC1 , XRCC6...
October 13, 2020: Cancers